Indeed, the major hurdle associated with the development of RB1 as a predictive marker of response to treatments is the lack of standardized methods to assess its functional status in tumor specimens [118] and several different approaches have been used to detect the different mechanisms whereby RB1 is functionally inactivated in cancer (Table 1). This evidence concerns the gene RB1 and cancer.